Pharmsville Q1 2026: Sales Decline, Operating Loss, Net Profit from Financial Gains, KFDA Approval for Anti-Obesity Probiotic

Consolidated sales of 2,486 million KRW (down 25.5% from 3,338 million in the prior-year quarter), operating loss of 55 million KRW.
Net profit of 1,215 million KRW (up from 1,105 million) due to financial gains from asset valuation (1,210 million KRW).
Debt ratio of 2.34%, very stable financial structure with no borrowings.
Cash and cash equivalents surged to 6.5 billion KRW from 1.7 billion at year-end.
In February 2026, KFDA approved 'Wilac D001' anti-obesity probiotic as an individual recognition raw material (including 31 PCT patent applications).
R&D expenses of 290 million KRW continued for microbiome and natural product development.
Holding 201,220 treasury shares but no cancellation or disposal plans.
No dividend paid (possible per articles but not executed).